OnKure Therapeutics, Inc.
OKUR
$2.53
-$0.01-0.39%
NASDAQ
| 12/31/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 4.11M | 3.59M | 1.27M | 1.07M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 17.85M | 14.34M | 9.83M | 9.89M | |
| Operating Income | -17.85M | -14.34M | -9.83M | -9.89M | |
| Income Before Tax | -17.44M | -14.14M | -9.54M | -9.46M | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -17.44M | -14.14M | -9.54M | -9.46M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -17.44M | -14.14M | -9.54M | -9.46M | |
| EBIT | -17.85M | -14.34M | -9.83M | -9.89M | |
| EBITDA | -17.74M | -14.23M | -9.72M | -9.78M | |
| EPS Basic | -1.37 | -1.06 | -0.72 | -0.71 | |
| Normalized Basic EPS | -0.81 | -0.66 | -0.45 | -0.44 | |
| EPS Diluted | -1.37 | -1.06 | -0.72 | -0.71 | |
| Normalized Diluted EPS | -0.81 | -0.66 | -0.45 | -0.44 | |
| Average Basic Shares Outstanding | 12.77M | 13.37M | 13.31M | 13.34M | |
| Average Diluted Shares Outstanding | 12.77M | 13.37M | 13.31M | 13.34M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |